nasopharyngeal carcinoma
Conditions
Interventions
SBRT group:SBRT
Sponsors
Zhejiang Cancer Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1) Local and/or regional recurrence were occured more than one year after radiotherapy, and unfit for operation; 2) Aged 18-70years; 3) Local and/or regional recurrence were histopathologically proven; 4) Clinical stage was defined as rII- IVa according to the eight edition of the AJCC; 5) KPS>70 or ECOG 0-1; 6) No radiotherapy for recurrent lesion, chemotherapy, immunotherapy, etc. 7) No contraindications for chemotherapy, immunotherapy and radiotherapy; 8) Adequate bone marrow/liver and kidney function reserve is expected to successfully complete immunotherapy and chemotherapy; 9) Understanding the study and signing the informed consent form; 10) Completing research related questionnaire survey as required.
Exclusion criteria
Exclusion criteria: 1) With other malignancies; 2) Severe digestive disease; 3)Severe cardiopulmanary, liver and kidney dysfunction; 4) Previously received PD-1 antibody therapy or other immunotherapy targeting PD-1/PD-L1; 5) With autoimmune disease or immune deficiency; 6)Vulnerable groups,including peaple with mental illness, with cgnitive impairment, critically ill patients, minors, pregnant women, etc; 7) Allergic to any PD-1 antibody component or macromolecular protein;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1-year local/ regional recurrence free survival rate;Progression free survival; | — |
Secondary
| Measure | Time frame |
|---|---|
| Objective response rate;1-year overall survival rate;Quality of life;safety; | — |
Countries
China
Contacts
Public ContactWang Fangzheng
Zhejiang Cancer Hospital
Outcome results
None listed